Adverum Biotechnologies announced its investigational new drug application is now active for its planned phase 1 study of ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration.
The gene therapy candidate ADVM-022 uses a propriety vector capsid (AAV.7m8) to deliver, in one intravitreal injection, potentially sustained therapeutic levels of aflibercept, which could minimize the burden of frequent anti-VEGF injections, according to a company press release.
The multicenter, open-label, dose escalation trial is designed to assess the tolerability and
Uncategorized